It has also been documented by analyzing ctDNA and imaging studies in patients with ALK-positive NSCLC who experienced disease progression while on ALK TKIs that there is a significant correlation between ctDNA yield and disease burden on imaging [62]. This evidence concerns the gene ALK and non-small cell lung carcinoma.